Tonix Pharmaceuticals has announced promising preclinical findings regarding its investigational candidates TNX-1700 and TNX-4700, presented at the AACR Annual Meeting 2026. TNX-1700, a TFF2-albumin fusion protein, demonstrated the ability to reverse aging-associated gastric inflammation and significantly reduce tumor progression in aged gastric microenvironments in preclinical models. Meanwhile, TNX-4700, a human anti-BTLA monoclonal antibody, exhibited potent binding and functional antagonism, positioning it as a potential therapeutic for various cancers.

The significance of these findings lies in TNX-1700’s mechanism of action, which addresses IL-1β-driven inflammation linked to aging and gastric cancer. In aged mice, a decline in TFF2 levels correlated with increased IL-1β and heightened susceptibility to tumor progression. Treatment with TNX-1700 not only reversed this inflammation but also enhanced anti-tumor immunity, particularly when combined with PD-1 inhibitors. This suggests that TNX-1700 could serve as a critical component in overcoming therapeutic resistance in gastric cancer, a common challenge in oncology.

The implications for the field are substantial. The ability of TNX-1700 to target the CXCR4-driven myeloid axis and normalize cancer-induced myelopoiesis may shift current paradigms in cancer immunotherapy, particularly in how we approach treatment combinations. Furthermore, the favorable pharmacokinetics of TNX-1700, characterized by dose-independent, linear pharmacokinetics, support its potential as a viable therapeutic candidate, potentially accelerating timelines for clinical development in gastric and colorectal cancers. This research underscores the need for continued exploration of TFF2’s role in cancer biology and its therapeutic applications.

Source: globenewswire.com